CCM
SGMO

Cadian Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cadian Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-75,000
Closed -$1.36M – 89
2014
Q1 		$1.36M Buy
+75,000
New +$1.45M 0.03% 83

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cadian Capital Management's SGMO Position: Q2 2014 in Review

Cadian Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2014, closing a stake of 75,000 shares — an estimated $1.36M sold.

Cadian Capital Management first reported a position in SGMO in Q1 2014 and held it in 1 quarter. The position peaked at $1.36M in Q1 2014. 156 funds tracked by Wall St. Rank hold SGMO as of Q2 2014.

  • Cadian Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2014 after selling out during the quarter.
  • Cadian Capital Management sold 75,000 SANGAMO THERAPEUTICS INC shares in Q2 2014, an estimated $1.36M.
  • Cadian Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2014 and held it in 1 quarter.
  • Cadian Capital Management's SANGAMO THERAPEUTICS INC position peaked at $1.36M in Q1 2014.
  • 156 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2014.

Based on Cadian Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.